Eye neoplasm

Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

Retrieved on: 
Monday, May 3, 2021
Research, FDA, Clinical trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Oncology, Other Science, Eye neoplasm, Cancer, Bladder cancer, Choroidal Melanoma and Choroidal Metastasis, Light-Activated AU-011, Aura Biosciences, CHOROIDAL MELANOMA AND CHOROIDAL METASTASIS, LIGHT-ACTIVATED AU-011, AURA BIOSCIENCES

In both cell line panels, AU-011 demonstrated potent cell binding and cell killing activity with EC50 in the picomolar range.

Key Points: 
  • In both cell line panels, AU-011 demonstrated potent cell binding and cell killing activity with EC50 in the picomolar range.
  • The exposure of AU-011 in the tumor was approximately 5 times higher when AU-011 was administered by SC injection compared to IVT injection.
  • Aura has demonstrated the efficacy and safety of AU-011 in a Phase 1b/2 trial, including high rates of tumor control and vision preservation.
  • Future pipeline applications for Aura\xe2\x80\x99s technology include additional ocular oncology indications like choroidal metastases and solid tumor indications like non-muscle invasive bladder cancer.

Aura Biosciences Announces Publication of Data in Cancer Immunology Research, Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform with Broad Application in Cancer Treatment

Retrieved on: 
Wednesday, April 14, 2021
Science, Biotechnology, Research, Pharmaceutical, Optical, Oncology, Health, Clinical trials, 75th United States Congress, National Cancer Institute, Cancer, Eye neoplasm, Medicine, Causes of death, Health

The VDC technology platform is based on the discoveries of NIH Distinguished Investigator Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute (NCI).

Key Points: 
  • The VDC technology platform is based on the discoveries of NIH Distinguished Investigator Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute (NCI).
  • Aura has demonstrated the efficacy and safety of AU-011 in a Phase 1b/2 trial, including high rates of tumor control and vision preservation.
  • Future pipeline applications for Aura\xe2\x80\x99s technology include additional ocular oncology indications like choroidal metastases and solid tumor indications like non-muscle invasive bladder cancer.
  • For more information, visit www.aurabiosciences.com or follow us on Twitter .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210414005113/en/\n'

Aura Biosciences Announces AU-011 Data From Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting

Retrieved on: 
Tuesday, November 10, 2020
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Optical, Oncology, Other Science, Research, Science, Clinical trials, Clinical medicine, Medicine, Health, Eye color, Melanoma, Uveal melanoma, Eye neoplasm, Carol Shields, Intravitreal administration, J. William Harbour, DecisionDx-UM, Choroidal Melanoma, AU-011 (belzupacap sarotalocan), Suprachoroidal Administration, Aura Biosciences

The abstract details results from the ongoing intravitreal administration Phase 1b/2 clinical study and suprachoroidal administration Phase 2 clinical study evaluating AU-011 in patients with choroidal melanoma.

Key Points: 
  • The abstract details results from the ongoing intravitreal administration Phase 1b/2 clinical study and suprachoroidal administration Phase 2 clinical study evaluating AU-011 in patients with choroidal melanoma.
  • This late-breaking presentation will be given by Carol L. Shields, M.D., Director, Ocular Oncology Service at Wills Eye Hospital, and Professor of Ophthalmology at Thomas Jefferson University.
  • Details for the AAO 2020 presentations are as follows:
    Date and time: Available on demand Nov 14-15, 2020
    Choroidal melanoma is a rare and life-threatening type of eye cancer.
  • It is the most common primary intraocular cancer in adults and develops in the uveal tract of the eye.

Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatment

Retrieved on: 
Monday, October 12, 2020
Health, Clinical medicine, Medicine, Retinoblastoma, Leukocoria, Orphan drug, Blastoma, Eye neoplasm

OXFORD,England, Oct. 12, 2020 /PRNewswire/ -- Oxular Limited ("Oxular"), a leading retinal therapeutics development company, today announces it has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (U.S. FDA) for OXU-003, the Company's proprietary drug in development for the treatment of retinoblastoma.

Key Points: 
  • OXFORD,England, Oct. 12, 2020 /PRNewswire/ -- Oxular Limited ("Oxular"), a leading retinal therapeutics development company, today announces it has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (U.S. FDA) for OXU-003, the Company's proprietary drug in development for the treatment of retinoblastoma.
  • Retinoblastoma is a rare form of eye cancer that usually develops in early childhood, typically before the age of five.
  • The most common first sign of retinoblastoma is a visible whiteness in the pupil called "cat's eye reflex" or leukocoria.
  • The U.S. FDA grants Rare Paediatric and Orphan Drug designations to drugs intended for the treatment of rare diseases that primarily affect children ages 18 years or younger and fewer than 200,000 persons in the U.S.

Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatment

Retrieved on: 
Monday, October 12, 2020
Health, Clinical medicine, Medicine, Retinoblastoma, Leukocoria, Orphan drug, Blastoma, Eye neoplasm

OXFORD,England, Oct. 12, 2020 /PRNewswire/ -- Oxular Limited ("Oxular"), a leading retinal therapeutics development company, today announces it has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (U.S. FDA) for OXU-003, the Company's proprietary drug in development for the treatment of retinoblastoma.

Key Points: 
  • OXFORD,England, Oct. 12, 2020 /PRNewswire/ -- Oxular Limited ("Oxular"), a leading retinal therapeutics development company, today announces it has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (U.S. FDA) for OXU-003, the Company's proprietary drug in development for the treatment of retinoblastoma.
  • Retinoblastoma is a rare form of eye cancer that usually develops in early childhood, typically before the age of five.
  • The most common first sign of retinoblastoma is a visible whiteness in the pupil called "cat's eye reflex" or leukocoria.
  • The U.S. FDA grants Rare Paediatric and Orphan Drug designations to drugs intended for the treatment of rare diseases that primarily affect children ages 18 years or younger and fewer than 200,000 persons in the U.S.

Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery

Retrieved on: 
Friday, September 11, 2020
Visual system, Anatomy, Vision, Ophthalmology, Eye color, Melanoma, Uveal melanoma, Eye neoplasm, Choroid, Retina, Suprachoroidal drug delivery

Aura is using Clearsides SCS Microinjector to deliver AU-011 into the suprachoroidal space (SCS).

Key Points: 
  • Aura is using Clearsides SCS Microinjector to deliver AU-011 into the suprachoroidal space (SCS).
  • Auras preclinical data on suprachoroidal injection of AU-011 presented at the Association for Research in Vision and Ophthalmology conference can be accessed here .
  • Choroidal melanoma is a rare and aggressive type of eye cancer and is the most common primary intraocular tumor in adults.
  • Clearsides proprietary SCS Microinjector targets the suprachoroidal space (SCS) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs.

Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma

Retrieved on: 
Wednesday, July 15, 2020
Biotechnology, Health, Genetics, Clinical trials, Oncology, Melanoma, Medicine, Medical tests, Clinical medicine, Health, DecisionDx-UM, Uveal melanoma, Eye neoplasm, Uvea, J. William Harbour, DecisionDx-UM, Castle Biosciences

The article titled, Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis, was published in the peer-reviewed journal Ocular Oncology and Pathology.

Key Points: 
  • The article titled, Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis, was published in the peer-reviewed journal Ocular Oncology and Pathology.
  • UM patients face up to a 50% risk of metastasis, despite successful control of the primary tumor.
  • The multicenter CLEAR Registry Study (Clinical Application of DecisionDx-UM Gene Expression Assay Results) was designed to prospectively evaluate management plans and five-year clinical outcomes for UM patients tested with DecisionDx-UM as part of their clinical care.
  • It is estimated that nearly 8 in 10 patients diagnosed with uveal melanoma in the U.S. receive the DecisionDx-UM test as part of their diagnostic workup.

Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic

Retrieved on: 
Friday, March 27, 2020
Oncology, Health, Infectious diseases, Clinical trials, General Health, Biotechnology, Medicine, Clinical medicine, Health, Melanoma, Rare diseases, DecisionDx-UM, Uveal melanoma, Eye neoplasm, J. William Harbour, Retinoblastoma, Uvea, DecisionDx-UM, Castle Biosciences

The Collaborative Ocular Oncology Group (COOG) represents most major ocular oncology centers in North America who manage patients with uveal melanoma and other ocular tumors.

Key Points: 
  • The Collaborative Ocular Oncology Group (COOG) represents most major ocular oncology centers in North America who manage patients with uveal melanoma and other ocular tumors.
  • Currently, most ocular oncology experts continue to promptly see new patients with eye cancers, such as uveal melanoma, retinoblastoma, intraocular metastasis and vitreoretinal lymphoma.
  • Summary results are attached, and detailed results are available on the Castle Biosciences DecisionDx-UM page: https://castlebiosciences.com/products/decisiondx-um/ .
  • The attached results were prepared by the COOG, and Castle Biosciences makes no representation or warranty as to their accuracy or completeness.

Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting

Retrieved on: 
Monday, February 24, 2020
Research, FDA, Clinical trials, Biotechnology, Health, Optical, Other Science, Science, Oncology, Melanoma, Ophthalmology, Medicine, Organ systems, Uveal melanoma, Eye neoplasm, Uvea, Choroid, DecisionDx-UM, J. William Harbour, Choroidal Melanoma, Light-Activated AU-011, Aura Biosciences

I am proud of the work the company has done to make a significant progress in this ultra-rare disease.

Key Points: 
  • I am proud of the work the company has done to make a significant progress in this ultra-rare disease.
  • The updated data demonstrate that multiple administrations of light-activated AU-011 were well-tolerated.
  • Tumor control and vision preservation data continue to be supportive of the planned Phase 3 registration trial.
  • Choroidal melanoma is the most common primary intraocular tumor in adults and develops in the uveal tract of the eye.

Zelia M. Correa, M.D., Ph.D., Joins Sylvester Comprehensive Cancer Center And Bascom Palmer Eye Institute

Retrieved on: 
Friday, February 14, 2020
University of Miami, Healthcare in the United States, Health, Bascom Palmer Eye Institute, Eye neoplasm, Bascom, Leonard M. Miller School of Medicine, Johns Hopkins School of Medicine, Oncology, Eye care, J. William Harbour

MIAMI, Feb.14, 2020 /PRNewswire/ --Zelia M. Correa, M.D., Ph.D., one of the country's leading experts in the field of ocular oncology, has joined Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine as co-director of the ocular oncology service.

Key Points: 
  • MIAMI, Feb.14, 2020 /PRNewswire/ --Zelia M. Correa, M.D., Ph.D., one of the country's leading experts in the field of ocular oncology, has joined Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine as co-director of the ocular oncology service.
  • Ocular tumors can be benign or malignant and affect patients ranging from young children to older adults.
  • Correa most recently served as the Tom Clancy Endowed Professor of Ophthalmology at the Wilmer Eye Institute of Johns Hopkins University School of Medicine in Baltimore.
  • She will conduct her research at Bascom Palmer's ocular oncology laboratory.Read more: https://physician-news.umiamihealth.org/internationally-known-eye-cancer...
    View original content to download multimedia: http://www.prnewswire.com/news-releases/zelia-m-correa-md-phd-joins-sylv...
    SOURCE Sylvester Comprehensive Cancer Center; Bascom Palmer Eye Institute